MIT researchers have developed a way to control starfish egg cells' movement and shape using optogenetics, a technique that modifies cells to respond to light.

After 23andMe's bankruptcy, the NY and CA attorneys general warn customers to delete their data due to privacy risks, following the company's significant data breach and CEO's resignation. Experts advise proactive deletion of genetic information.

23andMe initiated a voluntary Chapter 11 bankruptcy process and is undergoing a court-supervised sale. CEO Anne Wojcicki steps down to potentially bid for the company.

Paul Arling, CEO of Universal Electronics, plans to retire by April 2025, prompting the search for a successor. He transformed the company into a leader in home entertainment technology.

MIT engineers developed a method for sustained drug release from a single injection, which could last for months or years, offering an alternative to frequent injections, with applications in contraception and various medical treatments.

A monolith with a QR code linked to a crypto site appeared at Seven Magic Mountains near Las Vegas and was quickly removed, signaling a possible publicity stunt.

Miaofang Chi and Rigoberto "Gobet" Advincula of ORNL were named Fellows of the Materials Research Society for their contributions to materials research.

The US Army is collaborating with ORNL to develop advanced nuclear systems, focusing on microreactors for military installations and national security.

MIT and NVIDIA researchers develop "HART," an AI tool for fast, high-quality image generation, combining diffusion and autoregressive models to enhance speed and detail.

The DHS and ORNL are developing tech to rapidly detect plant diseases and pests in US agricultural imports, aiming to safeguard agriculture and minimize commercial disruption.

Seattle Children's Research Institute reports a potential cure for Dravet syndrome, a rare epilepsy, using a new gene therapy developed by Dr. Franck Kalume and his team.

CARGO Therapeutics is downsizing staff and pausing drug development after a failed Phase 2 study, with Anup Radhakrishnan appointed as interim CEO. The company's value has dropped significantly.

ORNL hosted a training on nuclear safety, focusing on nondestructive assay techniques for detecting fissile material in equipment, to enhance nuclear accountability and criticality safety.